目的:研究阿托伐他汀对T2DM患者血清脂多糖(LPS)及相关炎症指标的影响.方法:将40例T2DM患者分为常规治疗组和阿托伐他汀治疗组.常规治疗组予以健康生活方式引导、常规降糖及基础临床干预,阿托伐他汀治疗组患者在常规治疗基础上给予阿托伐他汀10mg,1次/晚.治疗前及治疗12周后静脉采血,应用酶联免疫(ELISA法)检测血清重LPS、TNF-α、IL-6浓度.结果:治疗12周后,阿托伐他汀治疗组和常规治疗组血清LPS、TNF-α、IL-6浓度较治疗前降低;阿托伐他汀治疗组血清LPS、TNF-α、IL-6均低于常规治疗组,差异具有统计学意义.结论:阿托伐他汀能下调 T2DM患者的LPS表达,降低血清TNF-α、IL-6水平,减轻炎症反应,从而使T2DM患者获益.%Objective To investigateeffects of atorvastatin calcium on the serum lipopolysaccharide (LPS) and related in-flammatory factors in patients with type 2 diabetes. Methods Forty patients with type 2 diabetes were divided into the two groups: routinetreatmentgroup (20 cases), receiving routine therapy including health lifestyle guidance, routine blood glucose and basic clinical intervention; atorvastatin treatment group (20 cases), on the basis of routine treatmentadministered with the atorvastatin calcium 10mg onceday for 12 weeks. Blood samples were collected before and after 12 weeks of treatment. the level of serum LPS, TNF-αandIL-6 were measured by enzyme-linked immunosorbent assay (ELISA). Results After 12 weeks of treatment, the concentrations of LPS, TNF-α andIL-6 in the atorvastatin treatment group and the routinetreatment group were lower than before treatment, the difference was statistically significant. The levels of serum LPS, TNF-α and IL-6 in the atorv-astatin group were lower than those in the routine treatment group, the difference was statistically significant. Conclusion Ator-vastatin calcium can reduce the expression of LPS in patients with type 2 diabetes, and reduce the level of serum TNF-α and IL-6, reduce inflammation and thereby benefit T2DM patients.
展开▼
